Hamburg: FDA turns attention to lab-developed diagnostics

06/3/2013 | Forbes

The FDA could use its regulatory discretion to increase its scrutiny of laboratory-developed diagnostics, including those that are tools for personalized medicine, FDA Commissioner Dr. Margaret Hamburg said at a conference. Tests developed and offered by labs are becoming more complex, and the FDA wants to ensure that "the accuracy and clinical validity of high-risk tests are established before they come to market," she said.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL